enGene Therapeutics (ENGN) Cash from Investing Activities (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Cash from Investing Activities of $23.6 million for Q2 2026, up 31.71% year-over-year from $17.9 million in Q2 2025, and up 118.72% quarter-over-quarter from -$126.3 million in Q1 2026.
enGene Therapeutics (ENGN) Cash from Investing Activities (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Cash from Investing Activities for 4 consecutive years, with $23.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 31.71% year-over-year to $23.6 million; the TTM figure through Apr 2026 stood at -$60.8 million (up 68.39% YoY), while the FY2025 annual figure was -$25.1 million, up 80.04% from the prior year.
- Cash from Investing Activities rose to $23.6 million in Q2 2026 per ENGN's latest filing, from -$126.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $40.5 million in Q4 2025 and bottomed at -$126.3 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$18.1 million across 4 years, with a median of -$75500.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 90672.46% — and 2025, when it jumped 69050.0%.
- enGene Therapeutics' Cash from Investing Activities stood at -$138000.0 in 2023, then sank by 90672.46% to -$125.3 million in 2024, then soared by 132.33% to $40.5 million in 2025, then sank by 41.63% to $23.6 million in 2026.
- Business Quant data shows ENGN's Cash from Investing Activities at $23.6 million in Q2 2026, -$126.3 million in Q1 2026, and $40.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 23.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 23.64 Mn |
| Apr 30, 2026 | 23.64 Mn |
| Jan 31, 2026 | -126.30 Mn |
| Jan 31, 2026 | -126.30 Mn |
| Oct 31, 2025 | 40.50 Mn |
| Oct 31, 2025 | 40.50 Mn |
| Jul 31, 2025 | 1.38 Mn |
| Jul 31, 2025 | 1.38 Mn |
| Apr 30, 2025 | 17.95 Mn |
| Apr 30, 2025 | 17.95 Mn |
| Jan 31, 2025 | -84.96 Mn |
| Jan 31, 2025 | -84.96 Mn |
| Oct 31, 2024 | -125.27 Mn |
| Oct 31, 2024 | -125.27 Mn |
| Jul 31, 2024 | -2,000.00 |
| Jul 31, 2024 | -2,000.00 |
| Apr 30, 2024 | -179,000.00 |
| Apr 30, 2024 | -179,000.00 |
| Jan 31, 2024 | -506,000.00 |
| Jan 31, 2024 | -506,000.00 |